Paracetamol regulation findings
This article was originally published in The Tan Sheet
Executive Summary
Researchers found little evidence to support a hypothesis that regulations limiting paracetamol (acetaminophen) package sizes resulted in fewer poisoning deaths. Findings from an observational study by Oliver W. Morgan, Department of Primary Care and Social Medicine, Imperial College, London, et al., published in the April PLOS Medicine contradict a 2004 British Medical Journal study. The BMJ study found U.K. legislation limiting the number of acetaminophen and aspirin tablets sold in retail transactions reduced the number of overdose deaths (1"The Tan Sheet" Nov. 8, 2004, p. 9). Morgan et al. say decreased paracetamol-poisoning mortality coincided with the regulation. However, fatal poisonings involving aspirin and antidepressants also dropped. "This raises the question whether the decline in paracetamol deaths was due to the regulations or was part of a wider trend," they say...
You may also be interested in...
Acetaminophen-Related Overdose Deaths Down In UK Due To Law – BMJ
Legislation in the UK limiting the package sizes for acetaminophen and aspirin has reduced the number of deaths from overdose since its enactment in 1998, a study in the Oct. 29 British Medical Journal says
Sandoz Pioneers Posaconazole And Silodosin In Canada
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: